Biomedical literature, made navigable

Follow the entities shaping the evidence.

Discover articles through diseases, drugs, treatments, interventions, clinical instruments, institutions and funders extracted from the BMJ open corpus.

An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.

View all families

Organisations named as supporting, sponsoring, or funding research.

5,089 articles · 9,137 mentions Institutions

Universities, hospitals, research centres, networks, and public bodies.

11,350 articles · 22,378 mentions Drugs

Named medicines, compounds, vaccines, and pharmacological agents.

10,506 articles · 58,393 mentions Diseases

Named diseases, disorders, syndromes, injuries, and health conditions.

23,712 articles · 125,551 mentions Treatments

Clinical therapies and care approaches used to manage a condition.

7,227 articles · 16,644 mentions Interventions

Programmes, procedures, policies, and other actions being evaluated.

4,132 articles · 9,994 mentions Clinical instruments

Named questionnaires, scales, scores, indices, and other clinical outcome assessments.

945 articles · 1,957 mentions

29,499matching articles

244,054matching entity mentions

30popular entities listed

0%of mentions human-reviewed

Filter articles

Entity familyJournalContent resourceEvidence policyAutomated confidence floorArticles per pageReset filters

“Reviewed + threshold” includes every confirmed correction plus unreviewed proposals at or above the selected model score.

Matching articles

29,499 articles · page 124 of 2459

PO:13:336 Improvement of fatigue, musculoskeletal pain, morning stiffness and health-related quality of life in patients with SLE treated with dapirolizumab pegol: 48-week results from a phase 3 trial

lupusscimed · abstract · 2026-03-01 · 20 matching annotations

99.8%

SLE SLE-specific Lupus Dapirolizumab pegol NCT04294667 DZP prednisone LupusQoL

…raphics and disease characteristicsConclusions In patients with SLE, DZP+SOC treatment was associated with benefits in fatigue, mus…

PT2:06 Obinutuzumab induces histological remission and deep kidney parenchymal B-cell depletion in patients with lupus nephritis: exploratory analyses of the phase III regency trial

lupusscimed · abstract · 2026-03-01 · 20 matching annotations

96.4%

obinutuzumab lupus nephritis NCT04221477 OBI LN PBO

…es The REGENCY trial ( NCT04221477) demonstrated superiority of obinutuzumab (OBI) plus standard therapy (+ST) vs placebo (PBO) +ST in achie…

PT3:03 Rapid Oral glucocorticoid discontinuation or dose reduction among US patients with SLE receiving belimumab in a real-world setting

lupusscimed · abstract · 2026-03-01 · 20 matching annotations

95.9%

SLE Belimumab prednisone-equivalent lupus BEL LN GSK OGC

…roportion of moderate (74.3% vs 66.9%) or severe (3.7% vs 2.2%) SLE, but similar baseline organ damage ( table 1). Baseline moderat…

PT4:06 Four-year safety and efficacy of deucravacitinib in systemic lupus erythematosus: results from the phase 2 PAISLEY SLE trial

lupusscimed · abstract · 2026-03-01 · 20 matching annotations

99.7%

SLE Deucravacitinib

…ent safety profile and sustained efficacy of deucravacitinib in SLE with up to 4+ years of treatment, with no new safety signals de…

PT4:08 Impact of clinically important improvements in patient-reported outcomes on disease activity in patients with systemic lupus erythematosus treated with upadacitinib or placebo

lupusscimed · abstract · 2026-03-01 · 20 matching annotations

98.9%

SLE upadacitinib SLEek PBO UPA FACIT-fatigue

…ht the potential multifaceted benefits of UPA for patients with SLE.…

Cost-utility analysis of the Circle of Security-Parenting programme to reduce perinatal psychopathology in birthing parents in England

bmjopen · abstract · 2026-02-23 · 20 matching annotations

91.0%

EQ-5D National Health Service NHS COS-P TAU COS-P COSI

…r 12 months, derived from the 5-level EuroQol five-dimensional (EQ-5D-5L) questionnaire - responses. Costs were estimated from NHS and P…

Effects of acupuncture and mindfulness-based stress reduction for chronic non-specific low back pain: study protocol for a 2×2 factorial randomised controlled trial

bmjopen · abstract · 2026-02-12 · 20 matching annotations

99.0%

Pain Catastrophizing Scale Visual Analogue Scale Chronic non-specific low back pain (CNLBP)Acupuncture McGill Pain Questionnaire MBSR health education CNLBP

… (BAI), the Fear-Avoidance Beliefs Questionnaire (FABQ) and the Pain Catastrophizing Scale (PCS);Pain Sensitivity Questionnaire(PSQ); Pittsburgh Sleep Qua…

Occupational exposures among hairdressers and the occurrence of hormone-related conditions

oemed · abstract · 2026-02-12 · 20 matching annotations

98.1%

endometriosis fibroids ovarian cancer uterine cancer breast cancer bleach barbicide ovarian cancers perms formaldehyde+1 more

…er hairdressers. Ever-hairdressers had higher rates of incident endometriosis (477 cases, HR=1.61: 95% CI 1.08 to 2.38) compared with never-h…

Modernizing dual antiplatelet therapy in flow diversion: comparative outcomes after transition to universal prasugrel

neurintsurg · abstract · 2026-02-11 · 20 matching annotations

98.8%

prasugrel ticagrelor clopidogrel ticagrelor-treated prasugrel-based intracranial aneurysms DAPT FD

… regimens included ticagrelor (38.7%), clopidogrel (31.7%), and prasugrel (29.6%). At median 12-month follow-up, 97.8% of patients achiev…

Safety and tolerability of avacincaptad pegol in combination with ranibizumab in treatment-naïve patients with neovascular age-related macular degeneration: results from a phase 1 and phase 2a study

bmjophth · abstract · 2026-02-03 · 20 matching annotations

98.1%

ranibizumab geographic atrophy nAMD avacincaptad pegol neovascular age-related macular degeneration ACP NCT00709527

…herapy for geographic atrophy, administered in combination with ranibizumab, an approved therapy for neovascular age-related macular degene…

Patterns in meperidine distribution and associations with income and obesity in the USA and Puerto Rico between 2019 and 2023: a retrospective study

bmjopen · abstract · 2026-01-29 · 20 matching annotations

99.7%

meperidine adult obesity Centers for Disease Control and Prevention Drug Enforcement Administration

…lt obesity prevalence and median household income.Results Total meperidine distribution across the USA dropped by 57.8% from 2019 to 2023.…

Associations between obesity, metabolic syndrome and glaucoma in the National Institutes of Health ‘All of Us’ research programme

bjophthalmol · abstract · 2026-01-28 · 20 matching annotations

99.2%

glaucoma Obesity Metabolic Syndrome MetS AoU National Institutes of Health

…iations between (1) BMI, (2) CO, (3) WC, (4) MetS, (5) MSSS and glaucoma prevalence.Results Overweight (OR 0.80 (95% CI 0.74 to 0.86)) a…